Idarucizumab

CHEMBL3544996 Phase 4 Onaylandı Antibody
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

This monoclonal antibody fragment is used specifically to reverse the anticoagulant effects of dabigatran (a direct thrombin inhibitor) in emergency situations such as life-threatening bleeding or urgent surgery. It works by binding to dabigatran with very high affinity, neutralizing its blood-thinning activity within minutes. It is given as a single intravenous dose.

Terapötik Alanlar

Etki Mekanizması

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

This monoclonal antibody fragment is used specifically to reverse the anticoagulant effects of dabigatran (a direct thrombin inhibitor) in emergency situations such as life-threatening bleeding or urgent surgery. It works by binding to dabigatran with very high affinity, neutralizing its blood-thinning activity within minutes. It is given as a single intravenous dose.

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Yes, Idarucizumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3544996. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.